AnTolRx
About AnTolRx
AnTolRx develops patented tolerogenic nanoparticles that selectively target pathogenic immune cells to induce an anti-inflammatory response. This technology aims to improve treatment outcomes for autoimmune diseases, including Type 1 Diabetes, by addressing the underlying inflammation that contributes to disease progression.
```xml <problem> Current treatments for autoimmune diseases often broadly suppress the immune system, leading to increased risk of infection and other side effects. These treatments may also fail to specifically target the pathogenic immune cells driving the autoimmune response, resulting in incomplete disease control. </problem> <solution> AnTolRx is developing tolerogenic nanoparticles designed to selectively target and modulate pathogenic immune cells, inducing an anti-inflammatory response. This targeted approach aims to address the underlying inflammation that contributes to the progression of autoimmune diseases, such as Type 1 Diabetes, while minimizing off-target effects. The nanoparticles deliver a tolerogenic signal directly to the disease-causing immune cells, promoting immune tolerance and preventing further autoimmune damage. By selectively dampening the autoimmune response, AnTolRx's technology seeks to improve treatment outcomes and reduce the burden of systemic immunosuppression. </solution> <features> - Patented tolerogenic nanoparticle technology for targeted immune modulation - Selective targeting of pathogenic immune cells to induce an anti-inflammatory phenotype - Designed to promote immune tolerance and prevent further autoimmune damage - Potential for improved treatment outcomes and reduced side effects compared to broad immunosuppressants </features> <target_audience> The primary target audience includes individuals with autoimmune diseases, such as Type 1 Diabetes, and the healthcare providers who treat them. </target_audience> ```
What does AnTolRx do?
AnTolRx develops patented tolerogenic nanoparticles that selectively target pathogenic immune cells to induce an anti-inflammatory response. This technology aims to improve treatment outcomes for autoimmune diseases, including Type 1 Diabetes, by addressing the underlying inflammation that contributes to disease progression.
Where is AnTolRx located?
AnTolRx is based in Cambridge, United Kingdom.
When was AnTolRx founded?
AnTolRx was founded in 2015.
How much funding has AnTolRx raised?
AnTolRx has raised 4000000.
- Location
- Cambridge, United Kingdom
- Founded
- 2015
- Funding
- 4000000 0